Mifepristone Paternalism at the FDA

Journal of Law, Medicine and Ethics 51 (3):554-559 (2023)
  Copy   BIBTEX

Abstract

This article explores the role of the Food and Drug Administration (FDA) in drug approval and restrictions to mifepristone access in the context of historical regulation and current litigation.

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 93,127

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

OPRR and FDA propose revised expedited review categories.Helen McGough - 1997 - IRB: Ethics & Human Research 20 (1):9-11.
Riegel v. Medtronic, Inc.: Revisiting Pre-Emption for Medical Devices.Bruce Patsner - 2009 - Journal of Law, Medicine and Ethics 37 (2):305-317.
Challenges in the Federal Regulation of Pain Management Technologies.Lars Noah - 2003 - Journal of Law, Medicine and Ethics 31 (1):55-74.
Recent Developments in Health Law.Carmel Shachar & Pooja Nair - 2009 - Journal of Law, Medicine and Ethics 37 (3):523-530.
Recent Developments in Health Law.Carmel Shachar & Pooja Nair - 2009 - Journal of Law, Medicine and Ethics 37 (3):523-527.

Analytics

Added to PP
2023-12-14

Downloads
7 (#1,413,139)

6 months
7 (#491,177)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references